Cargando…

Side effects during chemotherapy predict tumour response in advanced colorectal cancer

To investigate whether a relationship between chemotherapy-associated adverse events and treatment efficacy exists, we have analysed the toxicity, objective response and survival data of 303 patients with advanced colorectal cancer. Patients were divided into two groups: the first with beneficial ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuell, B, Gruenberger, T, Kornek, G V, Dworan, N, Depisch, D, Lang, F, Schneeweiss, B, Scheithauer, W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361647/
https://www.ncbi.nlm.nih.gov/pubmed/16160693
http://dx.doi.org/10.1038/sj.bjc.6602783
_version_ 1782153265154097152
author Schuell, B
Gruenberger, T
Kornek, G V
Dworan, N
Depisch, D
Lang, F
Schneeweiss, B
Scheithauer, W
author_facet Schuell, B
Gruenberger, T
Kornek, G V
Dworan, N
Depisch, D
Lang, F
Schneeweiss, B
Scheithauer, W
author_sort Schuell, B
collection PubMed
description To investigate whether a relationship between chemotherapy-associated adverse events and treatment efficacy exists, we have analysed the toxicity, objective response and survival data of 303 patients with advanced colorectal cancer. Patients were divided into two groups: the first with beneficial effect (I, n=245), and the second with progressive disease (II, n=58). Differences in terms of incidence rates, type and severity of adverse events were analysed with univariate and multivariate models. The median number of side effects in group I was 6 vs 4 in group II (OR=1.342; P=0.0001). An inverse correlation between disease control and treatment tolerance was confirmed when side effects were analysed according to severity and type of treatment-associated toxicities (haematological: P=0.0005 vs nonhaematological P=0.0001). When median survival was analysed according to the number of adverse events, it was 10 (95% CI, 3–7), 16 (14–18), and 18 (16–20) months in case of 0–1, 2–5, and ⩾6 adverse events, respectively (P=0.01). In conclusion, the results of this analysis suggest that occurrence of side effects during chemotherapy in advanced colorectal cancer is an independent and reliable prognostic indicator for response and survival.
format Text
id pubmed-2361647
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23616472009-09-10 Side effects during chemotherapy predict tumour response in advanced colorectal cancer Schuell, B Gruenberger, T Kornek, G V Dworan, N Depisch, D Lang, F Schneeweiss, B Scheithauer, W Br J Cancer Clinical Study To investigate whether a relationship between chemotherapy-associated adverse events and treatment efficacy exists, we have analysed the toxicity, objective response and survival data of 303 patients with advanced colorectal cancer. Patients were divided into two groups: the first with beneficial effect (I, n=245), and the second with progressive disease (II, n=58). Differences in terms of incidence rates, type and severity of adverse events were analysed with univariate and multivariate models. The median number of side effects in group I was 6 vs 4 in group II (OR=1.342; P=0.0001). An inverse correlation between disease control and treatment tolerance was confirmed when side effects were analysed according to severity and type of treatment-associated toxicities (haematological: P=0.0005 vs nonhaematological P=0.0001). When median survival was analysed according to the number of adverse events, it was 10 (95% CI, 3–7), 16 (14–18), and 18 (16–20) months in case of 0–1, 2–5, and ⩾6 adverse events, respectively (P=0.01). In conclusion, the results of this analysis suggest that occurrence of side effects during chemotherapy in advanced colorectal cancer is an independent and reliable prognostic indicator for response and survival. Nature Publishing Group 2005-10-03 2005-09-13 /pmc/articles/PMC2361647/ /pubmed/16160693 http://dx.doi.org/10.1038/sj.bjc.6602783 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Schuell, B
Gruenberger, T
Kornek, G V
Dworan, N
Depisch, D
Lang, F
Schneeweiss, B
Scheithauer, W
Side effects during chemotherapy predict tumour response in advanced colorectal cancer
title Side effects during chemotherapy predict tumour response in advanced colorectal cancer
title_full Side effects during chemotherapy predict tumour response in advanced colorectal cancer
title_fullStr Side effects during chemotherapy predict tumour response in advanced colorectal cancer
title_full_unstemmed Side effects during chemotherapy predict tumour response in advanced colorectal cancer
title_short Side effects during chemotherapy predict tumour response in advanced colorectal cancer
title_sort side effects during chemotherapy predict tumour response in advanced colorectal cancer
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361647/
https://www.ncbi.nlm.nih.gov/pubmed/16160693
http://dx.doi.org/10.1038/sj.bjc.6602783
work_keys_str_mv AT schuellb sideeffectsduringchemotherapypredicttumourresponseinadvancedcolorectalcancer
AT gruenbergert sideeffectsduringchemotherapypredicttumourresponseinadvancedcolorectalcancer
AT kornekgv sideeffectsduringchemotherapypredicttumourresponseinadvancedcolorectalcancer
AT dworann sideeffectsduringchemotherapypredicttumourresponseinadvancedcolorectalcancer
AT depischd sideeffectsduringchemotherapypredicttumourresponseinadvancedcolorectalcancer
AT langf sideeffectsduringchemotherapypredicttumourresponseinadvancedcolorectalcancer
AT schneeweissb sideeffectsduringchemotherapypredicttumourresponseinadvancedcolorectalcancer
AT scheithauerw sideeffectsduringchemotherapypredicttumourresponseinadvancedcolorectalcancer